Compare Crispr Therapeutics AG (CRSP) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs LYFT Inc — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while LYFT Inc trades at $15.97 (market cap $5.93B). The key difference: LYFT Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| CRSP | LYFT | |
|---|---|---|
Market Cap | $4.97B | $5.93B |
Sector | Health | Industrials |
52-Week High | $76.78 | $24.57 |
52-Week Low | $44.34 | $12.65 |
Enterprise Value | $3.32B | $5.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Lyft trades at $15.67, up 0.38% today, with a bullish technical signal and positive cash flow trends. The stock shows attractive valuation metrics with P/E of 2.29 and P/S of 0.99, while recent earnings have been mixed with Q4 2025 beating expectations but Q1 2026 missing. Revenue growth continues with $6.32B in 2025, and the company maintains strong profitability with 43.82% net income margin. Analyst consensus is mixed with 37% buy ratings and $17.86 price target.
Lyft presents a compelling value opportunity with deep valuation discounts and improving fundamentals, though execution risks remain. The company's transition to profitability and strategic expansion into autonomous vehicles provide growth catalysts, but competitive pressures and earnings volatility require careful monitoring. The stock offers 14% upside to consensus target with manageable downside risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
